SecBot SecBot
DEFA14A ·Filed May 12, 2026

FONR

FONAR CORP
BEARISH
Impact 7/10
Horizondays Processed5mo ago SEC0001731122-26-000711
Proxy solicitation materials
Actionable Insight ▼ Bearish

The sharp deterioration in profitability and cash flow raises concerns about the company's standalone value ahead of the May 28 going-private vote. Monitor the merger vote outcome closely — if the deal fails, the stock could reprice lower given the weak operating trends.

DirectionBearish
Confidencehigh
Horizondays
Latest settled — T+5d ⚠ clustered
FONR ▲ 0.00% at T+5d
SHORT call ✗ call lost 0.00% · α vs SPY -1.16% · entry $18.86 → $18.86
Next anchor: T+20d due 5mo ago
Entry = T+0 close
May 12, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.00%
$18.86
settled 6mo ago
T+5d
0.00%
call 0.00% · α -1.16%
$18.86
settled 5mo ago
T+20d
Pending
due 5mo ago
T+60d
Pending
due 3mo ago

Price Chart

Loading chart...

Executive Summary

FONAR reported fiscal Q3 2026 results with revenue down 3% YoY to $26.5M, net income down 25% to $2.3M, and diluted EPS down 35% to $0.24. The filing also updates on the proposed management-led going-private transaction, with a stockholder vote scheduled for May 28, 2026.

Key Financial Metrics

Vote
merger approval
Meeting
2026-05-28

Key Facts

  • Q3 FY2026 revenue decreased 3% YoY to $26.5M from $27.2M
  • Net income decreased 25% to $2.3M from $3.1M
  • Diluted EPS decreased 35% to $0.24 from $0.37
  • Income from operations decreased 33% to $2.4M from $3.7M
  • Nine-month operating cash flow fell to $3.4M from $7.0M
  • Special meeting of stockholders scheduled for May 28, 2026 to vote on going-private merger
  • Share repurchase program remains suspended due to pending transaction

Financial Impact

Revenue decline of $0.7M (3%), net income decline of $0.8M (25%), EPS decline of $0.13 (35%) in the quarter

revenuenet incomeepsoperating incomeoperating cash flow

Risk Factors

  • Going-private transaction may not receive stockholder approval
  • Continued revenue and earnings decline could pressure valuation
  • Operating cash flow halved, limiting financial flexibility
  • Suspension of buyback removes a support mechanism for the stock

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001731122-26-000711
Document: fonar_defa14a.htm0001731122-26-000711
Document: 0001731122-26-000711-index-headers.html0001731122-26-000711
Document: 0001731122-26-000711-index.html0001731122-26-000711
Document: 0001731122-26-000711.txt0001731122-26-000711
6 reports for FONR
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for FONR — sortable, filterable
TypeNow
Jun 15, 2026
19w ago
15-12G
BEARISH ★ 7/10
—awaiting T+5——
Jun 3, 2026
20w ago
8-K
NEUTRAL ★ 7/10
$19.09awaiting T+5——
May 21, 2026
22w ago
DEFA14A
NEUTRAL ★ 3/10
$18.90 $19.11▲ +1.14%▼ −0.52%—
May 21, 2026
22w ago
8-K
NEUTRAL ★ 3/10
$18.90 $19.11▲ +1.14%▼ −0.52%—
May 12, 2026
23w ago
DEFA14A
BEARISH ★ 7/10
$18.86 $18.86· 0.00%▼ −1.16%—
May 12, 2026
23w ago
8-K
BEARISH ★ 6/10
$18.86 $18.86· 0.00%▼ −1.16%—
Showing 6 of 6

US Market Status

Market Closed — Opens in 7h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026